search
Back to results

Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients (ADO pMDI)

Primary Purpose

Asthma

Status
Completed
Phase
Phase 2
Locations
Poland
Study Type
Interventional
Intervention
Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1
CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).
BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)
CHF 1535 100/6 pMDI (Foster®) (CTR)
Sponsored by
Chiesi Farmaceutici S.p.A.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring adolescents, adults

Eligibility Criteria

12 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

- Inclusion criteria

Patients will be enrolled if they meet all of the following criteria:

  1. Male and female adolescents, aged ≥ 12 and < 18 years at the time of Screening Visit or male and female adults, aged ≥ 18 and ≤ 65 years at the time of Screening Visit.
  2. Written informed consent obtained by the patient in case of adult patients and by parents/legal representative and by the minor (according to local regulation).
  3. A diagnosis of asthma as defined in the GINA guidelines (updated 2010) 6 months before the screening visit.
  4. Male/female adolescent and adult patients with asthma stable enough, according to GINA guidelines (updated 2010) and based on the Investigator's opinion, to allow a wash out period from inhaled BDP of 2 days before each single day study treatments and any ICS other than BDP of 1 day before each single day study treatments.
  5. Male/female adolescents and adults asthmatic patients already treated with ICS or ICS/long-acting inhaled β2-agonists or using short-acting inhaled β2-agonists as reliever to control asthma symptoms.
  6. Adolescents and adults with a forced expiratory volume in one second (FEV1) > 70% of predicted values (% pred) after withholding short acting β2-agonist treatment for a minimum of 6 h prior to screening or 24 hours in case of long acting β2-agonist.
  7. Non- or ex-smokers who smoked less than 5 pack-years (e.g. < 20 cigarettes per day for 5 years) and stopped smoking for at least 1 year.
  8. A cooperative attitude and ability to be trained about the proper use of pMDI with and without a spacer device and compliant to study procedures.
  9. Body mass index (BMI) ≥18.5 and ≤ 32 kg/m2

    • Exclusion criteria

Patients will not be enrolled if one or more of the following criteria are present:

  1. Pregnant or breast-feeding female patients. Sexually active female not using efficient contraception throughout the entire study period (e.g. oestro-progestatives, condoms, intrauterine devices). A urinary pregnancy test will be performed at screening and treatment visits (mandatory in the adult population and at discretion of the investigator in the adolescent population) in women of childbearing potential;
  2. Having received an investigational drug within 2 months before the screening visit (Visit 1).
  3. Diagnosis of COPD, in the adult patients, as defined by the current GOLD guidelines (updated 2010).
  4. Known hypersensitivity to the active treatments.
  5. Inability to perform the required breathing technique and blood sampling.
  6. Hospitalization due to exacerbation of asthma within 1 month prior to the screening visit.
  7. Lower respiratory tract infection within 1 month prior to screening visit.
  8. Obesity, i.e. > 97% weight percentile by local standards.
  9. Significant medical history of and/or treatments for cardiac, renal, neurological, hepatic, endocrine diseases, that may interfere with patient's safety, compliance, or study evaluations, according to the Investigator's opinion;
  10. History of drug addiction or excessive use of alcohol (weekly intake in excess of 28 units alcohol; one unit being a glass of beer, wine or a measure of spirits), or excessive consumption of xanthine containing substances (daily intake in excess of 5 cups of coffee, tea, cola, etc) or psychological or other emotional problems likely to invalidate informed consent, or limit the ability of the subject to comply with the protocol requirements;
  11. Treatment with a xanthine derivative (e.g. theophylline) formulations in the 4 weeks prior to screening;
  12. Blood donation (450 mL or more) (for the adult population) or significant blood loss in the 12 weeks before the screening visit.

Sites / Locations

  • Uniwersytecki Szpital Kliniczny nr 1

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

CHF 1535 100/6 pMDI (Foster®) TEST 1

CHF 1535 100/6 pMDI (Foster®) AeroChamber Plus™ (TEST 2).

(Qvar®: BDP 400 µg)+(Atimos®: formoterol 24 µg)

CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI

Arm Description

Adolescents CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI

CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ spacer device in adolescents (TEST 2)

BDP 100 µg pMDI, 4 puffs (Qvar®, total dose: BDP 400 µg) + formoterol fumarate 6 µg pMDI, 4 puffs (Atimos®, total dose: formoterol 24 µg)

Adults CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI

Outcomes

Primary Outcome Measures

AUC0-t of B17MP CHF 1535 100/6 pMDI with and without spacer vs free combination of BDP pMDI and formoterol pMDI
In adolescents, the systemic exposure of B17MP as AUC0-t, after inhalation of CHF 1535 100/6 pMDI with and without spacer device (AeroChamber Plus™) vs already licensed free combination of BDP pMDI and formoterol pMDI without spacer.

Secondary Outcome Measures

AUC0-t, AUC0-inf, Cmax, tmax and t½ for BDP and formoterol
In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs a free combination of licensed BDP and Formoterol pMDIs.
AUC0-0.5h, AUC0-inf, Cmax, tmax and t½ for B17MP
In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs a free combination of licensed BDP and Formoterol pMDIs.
plasma glucose and plasma potassium AUC0-t; Cmin; Tmin; Cmax; Tmax
In adolescents, after inhalation of CHF 1535 100/6 pMDI with and without spacer (AeroChamber Plus™)vs fre combination
Heart rate as AUC0-8h of CHF 1535 100/6 pMDI
In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs free combination
FEV1; time everaged FEV1 value AUC0-8h; peak FEV1
In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs a free combination of licensed BDP and Formoterol pMDIs.

Full Information

First Posted
October 4, 2012
Last Updated
July 30, 2020
Sponsor
Chiesi Farmaceutici S.p.A.
search

1. Study Identification

Unique Protocol Identification Number
NCT01803087
Brief Title
Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients
Acronym
ADO pMDI
Official Title
A SINGLE-DOSE, OPEN LABEL, RANDOMIZED, 3-WAY CROSSOVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 100/6 pMDI (FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARATE 6 µg) WITH OR WITHOUT SPACER DEVICE VERSUS THE FREE COMBINATION OF LICENSED BECLOMETHASONE pMDI AND FORMOTEROL pMDI IN ASTHMATIC ADOLESCENT PATIENTS AND ONE OPEN ARM FOR ADULT PATIENTS AS CONTROL GROUP TREATED WITH CHF 1535 100/6 pMDI.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2020
Overall Recruitment Status
Completed
Study Start Date
February 2012 (undefined)
Primary Completion Date
October 2012 (Actual)
Study Completion Date
October 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chiesi Farmaceutici S.p.A.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This clinical pharmacology want to investigate the systemic availability of BDP/B17MP (active metabolite of BDP) and formoterol after single oral inhalation of CHF 1535 100/6 pMDI with and without spacer device (AeroChamber Plus™) and in comparison to a free combination of BDP pMDI plus formoterol pMDI licensed products; this will be additionally compared to the systemic exposure in adults without the spacer device.
Detailed Description
The proposed clinical pharmacology study is aimed to investigate the systemic availability of BDP/B17MP (active metabolite of BDP) and formoterol after single oral inhalation of CHF 1535 100/6 pMDI (to reach a total dose of BDP 400 µg and formoterol 24 µg) with and without spacer device (AeroChamber Plus™) and in comparison to a free combination of BDP pMDI plus formoterol pMDI licensed products (to reach the same total dose of BDP and formoterol) in adolescent asthmatic patients. The systemic exposure to BDP/B17MP and formoterol after inhalation of CHF 1535 pMDI in adolescents will be additionally compared to the systemic exposure in adults without the spacer device. The chosen doses correspond to the maximum daily dose of the two components administered as fixed combination.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
adolescents, adults

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CHF 1535 100/6 pMDI (Foster®) TEST 1
Arm Type
Active Comparator
Arm Description
Adolescents CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
Arm Title
CHF 1535 100/6 pMDI (Foster®) AeroChamber Plus™ (TEST 2).
Arm Type
Active Comparator
Arm Description
CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ spacer device in adolescents (TEST 2)
Arm Title
(Qvar®: BDP 400 µg)+(Atimos®: formoterol 24 µg)
Arm Type
Active Comparator
Arm Description
BDP 100 µg pMDI, 4 puffs (Qvar®, total dose: BDP 400 µg) + formoterol fumarate 6 µg pMDI, 4 puffs (Atimos®, total dose: formoterol 24 µg)
Arm Title
CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
Arm Type
Active Comparator
Arm Description
Adults CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
Intervention Type
Drug
Intervention Name(s)
Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1
Intervention Type
Drug
Intervention Name(s)
CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).
Intervention Type
Drug
Intervention Name(s)
BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)
Other Intervention Name(s)
Free combination of BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) in adolescents (REF)
Intervention Type
Drug
Intervention Name(s)
CHF 1535 100/6 pMDI (Foster®) (CTR)
Other Intervention Name(s)
CHF 1535 100/6 pMDI (Foster®) in adults (CTR)
Primary Outcome Measure Information:
Title
AUC0-t of B17MP CHF 1535 100/6 pMDI with and without spacer vs free combination of BDP pMDI and formoterol pMDI
Description
In adolescents, the systemic exposure of B17MP as AUC0-t, after inhalation of CHF 1535 100/6 pMDI with and without spacer device (AeroChamber Plus™) vs already licensed free combination of BDP pMDI and formoterol pMDI without spacer.
Time Frame
: pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.
Secondary Outcome Measure Information:
Title
AUC0-t, AUC0-inf, Cmax, tmax and t½ for BDP and formoterol
Description
In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs a free combination of licensed BDP and Formoterol pMDIs.
Time Frame
: pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.
Title
AUC0-0.5h, AUC0-inf, Cmax, tmax and t½ for B17MP
Description
In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs a free combination of licensed BDP and Formoterol pMDIs.
Time Frame
: pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.
Title
plasma glucose and plasma potassium AUC0-t; Cmin; Tmin; Cmax; Tmax
Description
In adolescents, after inhalation of CHF 1535 100/6 pMDI with and without spacer (AeroChamber Plus™)vs fre combination
Time Frame
: pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.
Title
Heart rate as AUC0-8h of CHF 1535 100/6 pMDI
Description
In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs free combination
Time Frame
pre-dose (within 5 min from dosing), 5 min; 10 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.
Title
FEV1; time everaged FEV1 value AUC0-8h; peak FEV1
Description
In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs a free combination of licensed BDP and Formoterol pMDIs.
Time Frame
pre-dose; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
- Inclusion criteria Patients will be enrolled if they meet all of the following criteria: Male and female adolescents, aged ≥ 12 and < 18 years at the time of Screening Visit or male and female adults, aged ≥ 18 and ≤ 65 years at the time of Screening Visit. Written informed consent obtained by the patient in case of adult patients and by parents/legal representative and by the minor (according to local regulation). A diagnosis of asthma as defined in the GINA guidelines (updated 2010) 6 months before the screening visit. Male/female adolescent and adult patients with asthma stable enough, according to GINA guidelines (updated 2010) and based on the Investigator's opinion, to allow a wash out period from inhaled BDP of 2 days before each single day study treatments and any ICS other than BDP of 1 day before each single day study treatments. Male/female adolescents and adults asthmatic patients already treated with ICS or ICS/long-acting inhaled β2-agonists or using short-acting inhaled β2-agonists as reliever to control asthma symptoms. Adolescents and adults with a forced expiratory volume in one second (FEV1) > 70% of predicted values (% pred) after withholding short acting β2-agonist treatment for a minimum of 6 h prior to screening or 24 hours in case of long acting β2-agonist. Non- or ex-smokers who smoked less than 5 pack-years (e.g. < 20 cigarettes per day for 5 years) and stopped smoking for at least 1 year. A cooperative attitude and ability to be trained about the proper use of pMDI with and without a spacer device and compliant to study procedures. Body mass index (BMI) ≥18.5 and ≤ 32 kg/m2 Exclusion criteria Patients will not be enrolled if one or more of the following criteria are present: Pregnant or breast-feeding female patients. Sexually active female not using efficient contraception throughout the entire study period (e.g. oestro-progestatives, condoms, intrauterine devices). A urinary pregnancy test will be performed at screening and treatment visits (mandatory in the adult population and at discretion of the investigator in the adolescent population) in women of childbearing potential; Having received an investigational drug within 2 months before the screening visit (Visit 1). Diagnosis of COPD, in the adult patients, as defined by the current GOLD guidelines (updated 2010). Known hypersensitivity to the active treatments. Inability to perform the required breathing technique and blood sampling. Hospitalization due to exacerbation of asthma within 1 month prior to the screening visit. Lower respiratory tract infection within 1 month prior to screening visit. Obesity, i.e. > 97% weight percentile by local standards. Significant medical history of and/or treatments for cardiac, renal, neurological, hepatic, endocrine diseases, that may interfere with patient's safety, compliance, or study evaluations, according to the Investigator's opinion; History of drug addiction or excessive use of alcohol (weekly intake in excess of 28 units alcohol; one unit being a glass of beer, wine or a measure of spirits), or excessive consumption of xanthine containing substances (daily intake in excess of 5 cups of coffee, tea, cola, etc) or psychological or other emotional problems likely to invalidate informed consent, or limit the ability of the subject to comply with the protocol requirements; Treatment with a xanthine derivative (e.g. theophylline) formulations in the 4 weeks prior to screening; Blood donation (450 mL or more) (for the adult population) or significant blood loss in the 12 weeks before the screening visit.
Facility Information:
Facility Name
Uniwersytecki Szpital Kliniczny nr 1
City
Lodz
ZIP/Postal Code
90153
Country
Poland

12. IPD Sharing Statement

Citations:
PubMed Identifier
25808292
Citation
Kuna P, Govoni M, Lucci G, Scuri M, Acerbi D, Stelmach I. Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma. Br J Clin Pharmacol. 2015 Sep;80(3):569-80. doi: 10.1111/bcp.12640. Epub 2015 Jun 1.
Results Reference
result
Links:
URL
https://www.clinicaltrialsregister.eu/ctr-search/search?query=CCD-1104-PR-0062
Description
Study Record on EU Clinical Trials Register including results

Learn more about this trial

Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients

We'll reach out to this number within 24 hrs